Related Experiment Video
Updated: Apr 6, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
11.2K
Interaction of Glucagon G-Protein Coupled Receptor with Known Natural Antidiabetic Compounds: Multiscoring In Silico
1School of Biotechnology, Yeungnam University, Gyeongsan 712749, Republic of Korea.
Evidence-Based Complementary and Alternative Medicine : Ecam
|August 4, 2015
Summary
Curcumin and other natural compounds show promise as glucagon receptor (GCGR) antagonists. This study identified effective natural compounds for potential type 2 diabetes treatments, offering a new avenue for managing blood glucose levels.
Area of Science:
- Biochemistry
- Pharmacology
- Computational Chemistry
Background:
- The glucagon receptor (GCGR) is a G-protein coupled receptor (GPCR) crucial for regulating blood glucose.
- GCGR is a key therapeutic target for type 2 diabetes mellitus.
- Developing effective and safe GCGR antagonists remains a significant challenge.
Purpose of the Study:
- To identify natural compounds with potential GCGR antagonist activity.
- To evaluate the binding affinity of selected natural compounds to GCGR using in silico methods.
- To explore novel therapeutic strategies for type 2 diabetes treatment.
Main Methods:
- Literature review to select natural compounds with antidiabetic properties.
- Molecular docking simulations to predict binding potential against GCGR.
- Rescoring of top compounds using the x-score function.
- In silico analysis of atomic interactions between compounds and GCGR.
Main Results:
- Curcumin demonstrated the highest binding potential against GCGR among the tested natural compounds.
- Amorfrutin 1 and 4-hydroxyderricin also exhibited significant binding affinity.
- In silico analyses confirmed the binding accuracy and identified key interactions.
Conclusions:
- Curcumin is a potent natural GCGR antagonist with potential for type 2 diabetes therapy.
- Natural compounds like curcumin offer a promising alternative for diabetes management.
- Further experimental validation is warranted to confirm the therapeutic efficacy of these compounds.
More Related Videos
08:03Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
Published on: June 25, 2017
20.9K
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
1.0K
Related Concept Videos
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:06Oral Hypoglycemic Agents: Glinides
961
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
961
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
887
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
887
01:28Insulin: The Receptor and Signaling Pathways
6.1K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
6.1K
01:16Hormones Regulating Blood Glucose
8.6K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
8.6K